These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

175 related articles for article (PubMed ID: 2669065)

  • 1. Bisphosphonates: a new class of drugs in diseases of bone and calcium metabolism.
    Fleisch H
    Recent Results Cancer Res; 1989; 116():1-28. PubMed ID: 2669065
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Experimental basis for the use of bisphosphonates in Paget's disease of bone.
    Fleisch H
    Clin Orthop Relat Res; 1987 Apr; (217):72-8. PubMed ID: 3549097
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Bisphosphonates. Pharmacology and use in the treatment of tumour-induced hypercalcaemic and metastatic bone disease.
    Fleisch H
    Drugs; 1991 Dec; 42(6):919-44. PubMed ID: 1724640
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Bisphosphonates--history and experimental basis.
    Fleisch H
    Bone; 1987; 8 Suppl 1():S23-8. PubMed ID: 3318890
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Bisphosphonates: the first 40 years.
    Russell RG
    Bone; 2011 Jul; 49(1):2-19. PubMed ID: 21555003
    [TBL] [Abstract][Full Text] [Related]  

  • 6. New bisphosphonates in osteoporosis.
    Fleisch H
    Osteoporos Int; 1993; 3 Suppl 2():S15-22. PubMed ID: 8481594
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Mechanisms of action of the bisphosphonates.
    Fleisch H
    Medicina (B Aires); 1997; 57 Suppl 1():65-75. PubMed ID: 9567358
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Bisphosphonates in osteoporosis: an introduction.
    Fleisch H
    Osteoporos Int; 1993; 3 Suppl 3():S3-5. PubMed ID: 8298201
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Bisphosphonates, their mechanism of action and properties useful in the therapy of metabolic bone diseases].
    Fojtík Z; Kandusová M
    Vnitr Lek; 1997 Apr; 43(4):234-7. PubMed ID: 9601843
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical use of bisphosphonates.
    Devogelaer JP
    Curr Opin Rheumatol; 1996 Jul; 8(4):384-91. PubMed ID: 8864593
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Inhibitory effects of bisphosphonates on bone resorption].
    Shinoda H
    Nihon Yakurigaku Zasshi; 1995 May; 105(5):285-94. PubMed ID: 7628780
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The Pharmacological Profile of a Novel Highly Potent Bisphosphonate, OX14 (1-Fluoro-2-(Imidazo-[1,2-α]Pyridin-3-yl)-Ethyl-Bisphosphonate).
    Lawson MA; Ebetino FH; Mazur A; Chantry AD; Paton-Hough J; Evans HR; Lath D; Tsoumpra MK; Lundy MW; Dobson RL; Quijano M; Kwaasi AA; Dunford JE; Duan X; Triffitt JT; Jeans G; Russell RGG
    J Bone Miner Res; 2017 Sep; 32(9):1860-1869. PubMed ID: 28337806
    [TBL] [Abstract][Full Text] [Related]  

  • 13. In vitro and in vivo effects of tetrakisphosphonates on bone resorption, tumor osteolysis, ectopic calcification, and macrophages.
    Van Gelder JM; Breuer E; Schlossman A; Ornoy A; Mönkkönen J; Similä J; Klenner T; Stadler H; Krempien B; Patlas N; Golomb G
    J Pharm Sci; 1997 Mar; 86(3):283-9. PubMed ID: 9050794
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Bisphosphonates in the treatment of metabolic bone diseases.
    Rodan GA; Balena R
    Ann Med; 1993 Aug; 25(4):373-8. PubMed ID: 8217103
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cellular and molecular mechanisms of action of bisphosphonates.
    Rogers MJ; Gordon S; Benford HL; Coxon FP; Luckman SP; Monkkonen J; Frith JC
    Cancer; 2000 Jun; 88(12 Suppl):2961-78. PubMed ID: 10898340
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The pharmacology of bisphosphonates and new insights into their mechanisms of action.
    Russell RG; Rogers MJ; Frith JC; Luckman SP; Coxon FP; Benford HL; Croucher PI; Shipman C; Fleisch HA
    J Bone Miner Res; 1999 Oct; 14 Suppl 2():53-65. PubMed ID: 10510215
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Development of bisphosphonates.
    Fleisch H
    Breast Cancer Res; 2002; 4(1):30-4. PubMed ID: 11879557
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Structural requirements for bisphosphonate actions in vitro.
    van Beek E; Hoekstra M; van de Ruit M; Löwik C; Papapoulos S
    J Bone Miner Res; 1994 Dec; 9(12):1875-82. PubMed ID: 7872052
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The relationship between the chemistry and biological activity of the bisphosphonates.
    Ebetino FH; Hogan AM; Sun S; Tsoumpra MK; Duan X; Triffitt JT; Kwaasi AA; Dunford JE; Barnett BL; Oppermann U; Lundy MW; Boyde A; Kashemirov BA; McKenna CE; Russell RG
    Bone; 2011 Jul; 49(1):20-33. PubMed ID: 21497677
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Differential action of the bisphosphonates (3-amino-1-hydroxypropylidene)-1,1-bisphosphonate (APD) and disodium dichloromethylidene bisphosphonate (Cl2MDP) on rat macrophage-mediated bone resorption in vitro.
    Reitsma PH; Teitelbaum SL; Bijvoet OL; Kahn AJ
    J Clin Invest; 1982 Nov; 70(5):927-33. PubMed ID: 7130396
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.